Insider Stock Trading History of Kirk Randal J


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Kirk Randal J since year 2005. The trader's CIK number is 1091823. At the time of this reporting, Kirk Randal J is the Chief Executive Officer of Intrexon Corp . (stock ticker symbol XON). See this page for all insider trading activities at Intrexon Corp .

Note that in the past KIRK RANDAL J also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Kirk Randal J since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-08-11 XON Intrexon Corp Buy 132,625 18.85 2,499,981
2017-06-08 TBIO Transgenomic Inc Sale 1,975,000 1.00 1,975,000
2017-05-11 HALO Halozyme Therapeutics Inc Option Ex 10,000 10.37 103,699
2016-12-13 XON Intrexon Corp Buy 34,606 28.90 1,000,113
2016-05-13 XON Intrexon Corp Buy 41,830 23.92 1,000,573
2016-01-06 TBIO Transgenomic Inc Buy 4,474,825 1.00 4,474,825
2015-12-11 XON Intrexon Corp Buy 124,475 29.84 3,714,956
2015-12-07 XON Intrexon Corp Buy 237,525 30.69 7,289,642
2015-01-27 XON Intrexon Corp Buy 555,556 27.00 15,000,012
2014-05-09 XON Intrexon Corp Buy 15,088 13.42 202,480
2014-05-12 XON Intrexon Corp Buy 18,066 15.89 287,068
2014-05-13 XON Intrexon Corp Buy 32,019 15.63 500,456
2014-03-27 XON Intrexon Corp Buy 243,001 25.72 6,249,985
2013-08-13 XON Intrexon Corp Buy 1,887,500 16.00 30,200,000
2013-01-25 TBIO.OB Transgenomic Inc Buy 6,000,000 .00 0
2012-06-01 HALO Halozyme Therapeutics Inc Buy 99,080 7.39 732,201
2012-06-04 HALO Halozyme Therapeutics Inc Buy 89,646 7.37 660,691
2012-06-05 HALO Halozyme Therapeutics Inc Buy 5,463 7.48 40,863
2012-05-15 HALO Halozyme Therapeutics Inc Buy 427,581 7.35 3,142,720
2012-05-16 HALO Halozyme Therapeutics Inc Buy 344,910 7.44 2,566,130
2012-05-17 HALO Halozyme Therapeutics Inc Buy 299,007 7.50 2,242,552
2012-02-10 HALO Halozyme Therapeutics Inc Buy 1,360,000 10.61 14,429,600
2011-11-21 HALO Halozyme Therapeutics Inc Buy 56,477 8.04 454,075
2011-11-22 HALO Halozyme Therapeutics Inc Buy 55,146 8.11 447,234
2011-11-23 HALO Halozyme Therapeutics Inc Buy 166,100 8.00 1,328,800
2011-11-16 HALO Halozyme Therapeutics Inc Buy 175,520 8.19 1,437,508
2011-11-15 HALO Halozyme Therapeutics Inc Buy 242,704 8.18 1,985,318
2011-11-14 HALO Halozyme Therapeutics Inc Buy 220,000 8.13 1,788,600
2011-08-09 HALO Halozyme Therapeutics Inc Buy 738,331 5.88 4,341,386
2011-08-10 HALO Halozyme Therapeutics Inc Buy 261,669 6.13 1,604,030
2008-06-23 HALO Halozyme Therapeutics Inc Buy 713,232 5.71 4,072,554
2008-06-23 HALO Halozyme Therapeutics Inc Buy 28,463 5.54 157,571
2008-06-20 CLDA Clinical Data Inc Buy 5,985 16.49 98,692
2008-06-20 HALO Halozyme Therapeutics Inc Buy 175,500 5.85 1,026,674
2008-06-19 HALO Halozyme Therapeutics Inc Buy 59,900 6.02 360,598
2008-06-12 HALO Halozyme Therapeutics Inc Buy 57,000 5.42 308,940
2008-06-13 HALO Halozyme Therapeutics Inc Buy 45,725 5.53 252,859
2008-06-11 HALO Halozyme Therapeutics Inc Buy 115,439 5.27 608,363
2008-03-20 HALO Halozyme Therapeutics Inc Buy 1,264,657 6.09 7,701,761
2008-03-18 HALO Halozyme Therapeutics Inc Buy 207,546 4.57 948,485
2008-03-19 HALO Halozyme Therapeutics Inc Buy 886,650 5.80 5,142,570
2008-03-18 HALO Halozyme Therapeutics Inc Buy 207,546 4.57 948,485
2008-03-19 HALO Halozyme Therapeutics Inc Buy 886,650 5.80 5,142,570
2007-09-18 HALO Halozyme Therapeutics Inc Buy 15,489 8.87 137,387
2007-09-19 HALO Halozyme Therapeutics Inc Buy 23,085 9.00 207,765
2007-09-13 HTI Halozyme Therapeutics Inc Buy 65,713 8.74 574,331
2007-09-14 HTI Halozyme Therapeutics Inc Buy 127,693 8.71 1,112,206
2007-09-17 HTI Halozyme Therapeutics Inc Buy 238,020 8.66 2,061,253
2007-07-17 CLDA Clinical Data Inc Buy 2,250,000 22.00 49,500,000
2007-05-30 HTI Halozyme Therapeutics Inc Buy 3,500,000 9.17 32,095,000
2007-03-13 HTI Halozyme Therapeutics Inc Buy 46,080 7.93 365,414
2007-03-14 HTI Halozyme Therapeutics Inc Buy 30,200 7.91 238,882
2006-12-07 HTI Halozyme Therapeutics Inc Buy 336,200 5.55 1,865,910
2006-12-11 HTI Halozyme Therapeutics Inc Buy 80,000 6.16 492,800
2006-12-05 HTI Halozyme Therapeutics Inc Buy 53,500 2.84 151,940
2006-12-04 HTI Halozyme Therapeutics Inc Buy 11,500 2.86 32,890
2006-09-14 HTI Halozyme Therapeutics Inc Buy 20,000 2.50 50,000
2006-09-15 HTI Halozyme Therapeutics Inc Buy 102,500 2.50 256,250
2006-09-13 CLDA Clinical Data Inc Buy 30,571 15.42 471,404
2006-09-13 HTI Halozyme Therapeutics Inc Buy 74,000 2.50 185,000
2006-09-12 HTI Halozyme Therapeutics Inc Buy 20,000 2.58 51,600
2006-09-11 HTI Halozyme Therapeutics Inc Buy 3,200 2.54 8,128
2006-09-06 CLDA Clinical Data Inc Buy 42,000 14.95 627,900
2006-09-07 HTI Halozyme Therapeutics Inc Buy 15,000 2.51 37,650
2006-09-08 HTI Halozyme Therapeutics Inc Buy 30,500 2.52 76,860
2006-09-06 HTI Halozyme Therapeutics Inc Buy 17,300 2.56 44,288
2006-08-29 CLDA Clinical Data Inc Buy 12,621 15.00 189,315
2006-08-28 CLDA Clinical Data Inc Buy 13,990 15.07 210,829
2006-08-29 HTI Halozyme Therapeutics Inc Buy 23,000 2.60 59,800
2006-08-25 CLDA Clinical Data Inc Buy 7,697 13.48 103,755
2006-08-28 HTI Halozyme Therapeutics Inc Buy 60,000 2.56 153,600
2006-08-25 HTI Halozyme Therapeutics Inc Buy 110,900 2.50 277,250
2006-08-24 HTI Halozyme Therapeutics Inc Buy 93,300 2.50 233,250
2006-08-23 HTI Halozyme Therapeutics Inc Buy 6,700 2.49 16,683
2006-08-22 HTI Halozyme Therapeutics Inc Buy 17,600 2.46 43,296
2006-08-24 CLDA Clinical Data Inc Buy 10,693 13.17 140,826
2006-08-23 CLDA Clinical Data Inc Buy 12,500 12.97 162,125
2006-08-22 CLDA Clinical Data Inc Buy 4,012 12.30 49,347
2006-08-21 HTI Halozyme Therapeutics Inc Buy 12,500 2.46 30,750
2006-08-17 HTI Halozyme Therapeutics Inc Buy 94,100 2.46 231,486
2006-08-18 HTI Halozyme Therapeutics Inc Buy 3,500 2.42 8,470
2006-05-18 CLDA Clinical Data Inc Buy 100,000 20.00 2,000,000
2006-05-18 CLDA Clinical Data Inc Buy 100,000 20.00 2,000,000
2005-09-01 NRPH New River Pharmaceuticals Inc Sale 11,919 41.74 497,510
2005-06-15 NRPH New River Pharmaceuticals Inc Sale 187,000 30.00 5,610,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kirk Randal J (Chief Executive Officer of Intrexon Corp at the time of this reporting) see the Securities and Exchange Commission (SEC) website.